Adamis Pharmaceuticals Corp

+0.04 (+9.02%)
Earnings Announcements

Adamis Pharmaceuticals Announces Results Of Tempol In Omicron Virus Challenge In Hamster Model

Published: 03/22/2022 11:52 GMT
Adamis Pharmaceuticals Corp (ADMP) - Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model.
Adamis Pharmaceuticals Corp - in Our Hamster Model Using High Doses of Omicron Virus, We Observe Significant Pulmonary Inflammation.
Adamis Pharmaceuticals Corp - Recent Tempol Animal Study Shows Significant Decrease in Lung Inflammation in Hamsters Given High Doses of Omicron.
Adamis Pharmaceuticals Corp - Animal Study Results to Date Support Design of Our Ongoing Clinical Study in Humans.
Revenue is expected to be $1.84 Million
Adjusted EPS is expected to be -$0.04

Next Quarter Revenue Guidance is expected to be $3.99 Million
Next Quarter EPS Guidance is expected to be -$0.03

More details on our Analysts Page.